Trial Information
Tumor and Treatments Impact on Neurocognitive Functions and Quality of Life of Patients With OMS Grade II Glioma: Multicentric Prospective Study
Inclusion Criteria:
- OMS grade II glioma
- signed informed consent
- age >=18
- IK >=80%
- ability to read, write and undertand French
Exclusion Criteria:
- glioma localized to brainstem
- other neurologic or psychiatric disease
- history of other malignancies, other than curatively treated in-situ carcinoma of the
cervix or basal cell carcinoma of the skin, or any other curatively treated cancer
with no sign of recurrence within 5 years prior to randomization
- neuroleptic concomitant treatment
- pregnant or lactating women
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
MoCA test
Outcome Time Frame:
36 months
Safety Issue:
No
Principal Investigator
Marie-Pierre SUNYACH, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Centre Léon Bérard, Lyon - FRANCE
Authority:
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study ID:
TUMEURS GLIALES
NCT ID:
NCT01305122
Start Date:
February 2011
Completion Date:
February 2019
Related Keywords:
- OMS Grade II Glioma
- Glioma
- Neurocognitive functions
- Glioma